According to the Leukemia & Lymphoma Society, the world’s largest voluntary health agency dedicated to blood cancer, In 2018, 60,300 people are expected to be diagnosed with leukemia and that there are an estimated 381,774 people living with or in remission from leukemia in the US. In 2010 to 2014, leukemia was the sixth most common cause of cancer deaths in both men and women. However, the overall picture has been improving over the last decade. The overall five-year relative survival rate for leukemia has more than quadrupled since 1960. From 1960 to 1963, the five-year relative survival rate among whites (only data available) with leukemia was 14 percent. From 1975 to 1977, the five-year relative survival rate for the total population with leukemia was 34.1 percent, and from 2007 to 2013, the overall relative survival rate was 63.7 percent. Acute myeloid leukemia (AML), the most common type of adult leukemia, is a cancer of the blood-forming cells of the bone marrow. Currently, most patients with AML are treated with standard chemotherapy. But recent scientific advances have revealed that there are many forms of the disease, each with different specific genetic changes that may affect cancer growth and treatment. Active biotech and pharma companies in the markets this week include Moleculin Biotech, Inc. (NASDAQ:MBRX), Akari Therapeutics, Plc (NASDAQ: AKTX), Eli Lilly and Company (NYSE: LLY), Celgene Corporation (NASDAQ: CELG), Geron Corporation (NASDAQ: GERN).
The society says that: “Taking part in a clinical trial may be the best treatment choice for some acute myeloid leukemia (AML) patients. Clinical trials are under way for patients at every treatment stage and for patients in remission. Virtually all of today’s standard treatments for cancer are based on previous clinical trials.”